Report cover image

China Myasthenia Gravis Treatment Market By Drug class (Monoclonal antibodies, Intravenous immunoglobulin, Others), By Age group (Below 55 years, Above 55 years), By Distribution channel (Hospital pharmacies, Drug store and retail pharmacies, Online provi

Publisher Allied Market Research
Published May 02, 2023
Length 79 Pages
SKU # ALMR18790281

Description

China Myasthenia Gravis Treatment Market By Drug class (Monoclonal antibodies, Intravenous immunoglobulin, Others), By Age group (Below 55 years, Above 55 years), By Distribution channel (Hospital pharmacies, Drug store and retail pharmacies, Online providers): Opportunity Analysis and Industry Forecast, 2023-2032


The China myasthenia gravis treatment market is anticipated to witness notable growth during the forecast period. Myasthenia gravis is an autoimmune neuromuscular disorder, which causes muscle weakness and tiredness. Rise in prevalence of myasthenia gravis cases in China coupled with positive reimbursement plans is expected to drive the market growth during the forecast period.

The key factor driving the growth of the China myasthenia gravis therapy market is increase in prevalence of myasthenia gravis in China. According to Statista, the prevalence of myasthenia gravis in China was estimated to be over 4,000 situations in 2019, and this number is expected to rise due to enhanced analysis abilities and recognition of the disease. This is anticipated to provide a massive demand for myasthenia gravis treatments. Furthermore, increase in R&D activities from the government of China and various health care organizations in the direction of guaranteeing the accessibility of various treatments is expected to augment the market growth.

In addition, the availability of different reimbursement plans by local, state, and national authorities is expected to be a crucial factor sustaining the growth of the market.

However, high cost associated with the diagnosis and treatment of myasthenia gravis is expected to be a significant factor limiting the growth of the China myasthenia gravis treatment market. Furthermore, availability of medicines of comparable effectiveness at more affordable rates is expected to hamper the market growth.

On the other hand, increase in focus of the market players on developing awareness regarding the disorder is expected to be a major factor to provide new avenues for the growth of the market. In addition, rise in federal government initiatives to promote the incorporation of new technologies in the field of medical diagnosis and treatment of myasthenia gravis is expected to fuel the growth of the China myasthenia gravis treatment market.

The China myasthenia gravis treatment market is expected to witness new trends in the upcoming years. This is attributed to shift from conventional treatment to advanced treatments such as monoclonal antibodies and intravenous immunoglobulin injections. In addition, increase in the number of collaborations between healthcare companies and scholastic institutes to establish new treatments for the condition is anticipated to provide lucrative opportunities for the growth of the market. Furthermore, the market players are focusing on advertising, marketing, and providing new service designs to increase their market share.

The China myasthenia gravis treatment market is expected to witness considerable growth due to the advancement of new products in the upcoming years. The businesses are focusing on introducing new treatments that provide effectiveness and long-lasting safety. Furthermore, businesses are focusing on research activities regarding the growth of new treatments that improve the lifestyle of people with myasthenia gravis. In addition, market players are focusing on creating consumer awareness about battling myasthenia gravis prevalence through different programs such as individual education and counseling.

Moreover, the market players are focusing on providing products with competitive rates in the market to increase the demand for their products. In addition, they are focused on creating new products which are cost-effective to make them available to more patients.

The Porter's five forces analysis is helpful to understand the market intensity of the China myasthenia gravis treatment market. It includes the bargaining power of buyers, the bargaining power of suppliers, the threat of substitutes, the threat of new entrants and the competition among competitive rivalry. The bargaining power of suppliers is moderate due to the existence of a few distributors in the market. The bargaining power of buyers is high due to upsurge in demand for new and economical treatments. The threat of new entrants is low due to the presence of a couple of big companies having a syndicate in the market. The threat of substitutes is moderate due to the availability of treatments for myasthenia gravis.  The competitive rivalry between the existing market players is high due to the existence of a few huge companies.

The China myasthenia gravis treatment market is expected to witness significant growth in the upcoming years due to surge in prevalence of myasthenia gravis in China. Furthermore, government initiatives in campaigns for the advancement of new treatments, availability of reimbursement policies, and initiatives to promote consumer awareness regarding prevalence of myasthenia gravis are expected to be the major factor driving the market growth. However, the availability of medications of similar effectiveness at more affordable prices is expected to act as a key restraint for the market growth.

Key players included in the report are Nippon Boehringer Ingelheim, Yifan Pharmaceutical, Novartis, Shenzhen Salubris Pharmaceuticals, Shanghai Hainuo Bio Pharm, Shanghai Sanochemia Pharmaceuticals, Celgene Corporation, Pfizer, Gilead Sciences, Bayer AG.

The myasthenia gravis treatment market is segmented into drug class, and distribution channel. In terms of drug class, it is bifurcated into monoclonal antibodies, intravenous immunoglobulin, others. Based on the distribution channel, below 55 Years, above 55 Years.

Key Benefits For Stakeholders

Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.

Analyze the key strategies adopted by major market players in China Myasthenia Gravis treatment market.

Assess and rank the top factors that are expected to affect the growth of China Myasthenia Gravis treatment market.

Top Player positioning provides a clear understanding of the present position of market players.

Detailed analysis of the China Myasthenia Gravis treatment market segmentation assists to determine the prevailing market opportunities.

Identify key investment pockets for various offerings in the market.
Product Benchmarking / Product specification and applications
Upcoming/New Entrant by Regions
Patient/epidemiology data at country, region, global level
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
SWOT Analysis

Key Market Segments

By Age group

Below 55 years
Above 55 years

By Drug class

Monoclonal antibodies
Intravenous immunoglobulin
Others

By Distribution channel

Hospital pharmacies
Drug store and retail pharmacies
Online providers

Key Market Players

Nippon Boehringer Ingelheim
Yifan Pharmaceutical
Novartis
Shenzhen Salubris Pharmaceuticals
Shanghai Hainuo Bio Pharm
Shanghai Sanochemia Pharmaceuticals
Celgene Corporation
Pfizer
Gilead Sciences
Bayer AG

Please Note: It will take 7-10 business days to complete the report upon order confirmation. 

Table of Contents

79 Pages
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits to the Stakeholders
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Impacting Factors
3.2.2. Top Investment Pockets
3.3. Porter’s Five Forces Analysis
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: CHINA MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS
4.1. Overview
4.1.1. Market Size and Forecast, By Drug class
4.2. Monoclonal antibodies
4.3. Intravenous immunoglobulin
4.4. Others
CHAPTER 5: CHINA MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP
5.1. Overview
5.1.1. Market Size and Forecast, By Age group
5.2. Below 55 years
5.3. Above 55 years
CHAPTER 6: CHINA MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market Size and Forecast, By Distribution channel
6.2. Hospital pharmacies
6.3. Drug store and retail pharmacies
6.4. Online providers
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top player positioning, 2022
CHAPTER 8: COMPANY PROFILES
8.1. Company 1
8.1.1. Company overview
8.1.2. Key Executives
8.1.3. Company snapshot
8.1.4. Operating business segments
8.1.5. Product portfolio
8.1.6. Business performance
8.1.7. Key strategic moves and developments
8.2. Company 2
8.2.1. Company overview
8.2.2. Key Executives
8.2.3. Company snapshot
8.2.4. Operating business segments
8.2.5. Product portfolio
8.2.6. Business performance
8.2.7. Key strategic moves and developments
8.3. Company 3
8.3.1. Company overview
8.3.2. Key Executives
8.3.3. Company snapshot
8.3.4. Operating business segments
8.3.5. Product portfolio
8.3.6. Business performance
8.3.7. Key strategic moves and developments
8.4. Company 4
8.4.1. Company overview
8.4.2. Key Executives
8.4.3. Company snapshot
8.4.4. Operating business segments
8.4.5. Product portfolio
8.4.6. Business performance
8.4.7. Key strategic moves and developments
8.5. Company 5
8.5.1. Company overview
8.5.2. Key Executives
8.5.3. Company snapshot
8.5.4. Operating business segments
8.5.5. Product portfolio
8.5.6. Business performance
8.5.7. Key strategic moves and developments
8.6. Company 6
8.6.1. Company overview
8.6.2. Key Executives
8.6.3. Company snapshot
8.6.4. Operating business segments
8.6.5. Product portfolio
8.6.6. Business performance
8.6.7. Key strategic moves and developments
8.7. Company 7
8.7.1. Company overview
8.7.2. Key Executives
8.7.3. Company snapshot
8.7.4. Operating business segments
8.7.5. Product portfolio
8.7.6. Business performance
8.7.7. Key strategic moves and developments
8.8. Company 8
8.8.1. Company overview
8.8.2. Key Executives
8.8.3. Company snapshot
8.8.4. Operating business segments
8.8.5. Product portfolio
8.8.6. Business performance
8.8.7. Key strategic moves and developments
8.9. Company 9
8.9.1. Company overview
8.9.2. Key Executives
8.9.3. Company snapshot
8.9.4. Operating business segments
8.9.5. Product portfolio
8.9.6. Business performance
8.9.7. Key strategic moves and developments
8.10. Company 10
8.10.1. Company overview
8.10.2. Key Executives
8.10.3. Company snapshot
8.10.4. Operating business segments
8.10.5. Product portfolio
8.10.6. Business performance
8.10.7. Key strategic moves and developments
LIST OF TABLES
TABLE 01. CHINA MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 02. CHINA MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 03. CHINA MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 04. COMPANY 1: KEY EXECUTIVES
TABLE 05. COMPANY 1: COMPANY SNAPSHOT
TABLE 06. COMPANY 1: OPERATING SEGMENTS
TABLE 07. COMPANY 1: PRODUCT PORTFOLIO
TABLE 08. COMPANY 1: KEY STRATERGIES
TABLE 09. COMPANY 2: KEY EXECUTIVES
TABLE 10. COMPANY 2: COMPANY SNAPSHOT
TABLE 11. COMPANY 2: OPERATING SEGMENTS
TABLE 12. COMPANY 2: PRODUCT PORTFOLIO
TABLE 13. COMPANY 2: KEY STRATERGIES
TABLE 14. COMPANY 3: KEY EXECUTIVES
TABLE 15. COMPANY 3: COMPANY SNAPSHOT
TABLE 16. COMPANY 3: OPERATING SEGMENTS
TABLE 17. COMPANY 3: PRODUCT PORTFOLIO
TABLE 18. COMPANY 3: KEY STRATERGIES
TABLE 19. COMPANY 4: KEY EXECUTIVES
TABLE 20. COMPANY 4: COMPANY SNAPSHOT
TABLE 21. COMPANY 4: OPERATING SEGMENTS
TABLE 22. COMPANY 4: PRODUCT PORTFOLIO
TABLE 23. COMPANY 4: KEY STRATERGIES
TABLE 24. COMPANY 5: KEY EXECUTIVES
TABLE 25. COMPANY 5: COMPANY SNAPSHOT
TABLE 26. COMPANY 5: OPERATING SEGMENTS
TABLE 27. COMPANY 5: PRODUCT PORTFOLIO
TABLE 28. COMPANY 5: KEY STRATERGIES
TABLE 29. COMPANY 6: KEY EXECUTIVES
TABLE 30. COMPANY 6: COMPANY SNAPSHOT
TABLE 31. COMPANY 6: OPERATING SEGMENTS
TABLE 32. COMPANY 6: PRODUCT PORTFOLIO
TABLE 33. COMPANY 6: KEY STRATERGIES
TABLE 34. COMPANY 7: KEY EXECUTIVES
TABLE 35. COMPANY 7: COMPANY SNAPSHOT
TABLE 36. COMPANY 7: OPERATING SEGMENTS
TABLE 37. COMPANY 7: PRODUCT PORTFOLIO
TABLE 38. COMPANY 7: KEY STRATERGIES
TABLE 39. COMPANY 8: KEY EXECUTIVES
TABLE 40. COMPANY 8: COMPANY SNAPSHOT
TABLE 41. COMPANY 8: OPERATING SEGMENTS
TABLE 42. COMPANY 8: PRODUCT PORTFOLIO
TABLE 43. COMPANY 8: KEY STRATERGIES
TABLE 44. COMPANY 9: KEY EXECUTIVES
TABLE 45. COMPANY 9: COMPANY SNAPSHOT
TABLE 46. COMPANY 9: OPERATING SEGMENTS
TABLE 47. COMPANY 9: PRODUCT PORTFOLIO
TABLE 48. COMPANY 9: KEY STRATERGIES
TABLE 49. COMPANY 10: KEY EXECUTIVES
TABLE 50. COMPANY 10: COMPANY SNAPSHOT
TABLE 51. COMPANY 10: OPERATING SEGMENTS
TABLE 52. COMPANY 10: PRODUCT PORTFOLIO
TABLE 53. COMPANY 10: KEY STRATERGIES
LIST OF FIGURES
FIGURE 01. CHINA MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF CHINA MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032
FIGURE 03. TOP INVESTMENT POCKETS IN CHINA MYASTHENIA GRAVIS TREATMENT MARKET (2023-2032)
FIGURE 04. PORTER FIVE-1
FIGURE 05. PORTER FIVE-2
FIGURE 06. PORTER FIVE-3
FIGURE 07. PORTER FIVE-4
FIGURE 08. PORTER FIVE-5
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: CHINA MYASTHENIA GRAVIS TREATMENT MARKET
FIGURE 10. CHINA MYASTHENIA GRAVIS TREATMENT MARKET,BY DRUG CLASS, 2022 ($MILLION)
FIGURE 11. CHINA MYASTHENIA GRAVIS TREATMENT MARKET,BY AGE GROUP, 2022 ($MILLION)
FIGURE 12. CHINA MYASTHENIA GRAVIS TREATMENT MARKET,BY DISTRIBUTION CHANNEL, 2022 ($MILLION)
FIGURE 13. TOP WINNING STRATEGIES, BY YEAR
FIGURE 14. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 15. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 16. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 17. COMPETITIVE DASHBOARD
FIGURE 18. COMPETITIVE HEATMAP: CHINA MYASTHENIA GRAVIS TREATMENT MARKET
FIGURE 19. TOP PLAYER POSITIONING, 2022
FIGURE 20. COMPANY 1: NET SALES, 2020-2022* ($MILLION)
FIGURE 21. COMPANY 1: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 22. COMPANY 1: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 23. COMPANY 2: NET SALES, 2020-2022* ($MILLION)
FIGURE 24. COMPANY 2: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 25. COMPANY 2: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 26. COMPANY 3: NET SALES, 2020-2022* ($MILLION)
FIGURE 27. COMPANY 3: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 28. COMPANY 3: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 29. COMPANY 4: NET SALES, 2020-2022* ($MILLION)
FIGURE 30. COMPANY 4: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 31. COMPANY 4: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 32. COMPANY 5: NET SALES, 2020-2022* ($MILLION)
FIGURE 33. COMPANY 5: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 34. COMPANY 5: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 35. COMPANY 6: NET SALES, 2020-2022* ($MILLION)
FIGURE 36. COMPANY 6: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 37. COMPANY 6: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 38. COMPANY 7: NET SALES, 2020-2022* ($MILLION)
FIGURE 39. COMPANY 7: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 40. COMPANY 7: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 41. COMPANY 8: NET SALES, 2020-2022* ($MILLION)
FIGURE 42. COMPANY 8: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 43. COMPANY 8: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 44. COMPANY 9: NET SALES, 2020-2022* ($MILLION)
FIGURE 45. COMPANY 9: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 46. COMPANY 9: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 47. COMPANY 10: NET SALES, 2020-2022* ($MILLION)
FIGURE 48. COMPANY 10: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 49. COMPANY 10: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us